# A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors

> **NCT06063681** · PHASE1 · RECRUITING · sponsor: **Stingray Therapeutics** · enrollment: 25 (estimated)

## Conditions studied

- Advanced / Metastatic Solid Tumor

## Interventions

- **DRUG:** SR-8541A
- **DRUG:** Immune checkpoint inhibitor (ICI)

## Key facts

- **NCT ID:** NCT06063681
- **Lead sponsor:** Stingray Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-12
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06063681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06063681, "A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06063681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*